Amalgamated Financial’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Amalgamated Financial’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$262K	Buy	+5,296	New	+$254K	﹤0.01%	1786

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Amalgamated Financial's EGRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022: 5,296 shares worth $262K. The stake represents ﹤0.01% of the portfolio and ranks #1786 among its holdings.

160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

Amalgamated Financial held 5,296 shares of Eagle Pharmaceuticals, Inc. worth $262K as of Q1 2022.
Eagle Pharmaceuticals, Inc. was a new Amalgamated Financial position in Q1 2022.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1786 holding.
160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.